Clinical Factors Associated with Progression-Free Survival after Radioiodine Therapy for Pulmonary Metastases from Follicular Cell-Derived Thyroid Carcinoma: A Japanese Single-Center Study

This retrospective study aimed to identify clinical factors associated with progression-free survival (PFS) after radioiodine therapy (RAI) in Japanese patients with differentiated thyroid cancer (DTC) and pulmonary metastases. We included 74 patients with DTC and pulmonary metastases who underwent RAI at our institution between 2015 and 2023. Baseline clinicopathological, laboratory, and imaging variables at the initial RAI for pulmonary metastases were evaluated. PFS and overall survival (OS) were estimated using the Kaplan–Meier method. Because 27 PFS events were observed, associations with PFS were evaluated using Firth's penalized Cox regression. The primary multivariable model included the maximum pulmonary metastasis diameter, iodine-131 avidity, and extrapulmonary distant metastases. The cohort included 64 patients with papillary thyroid carcinoma, 7 with follicular thyroid carcinoma, and 3 with poorly differentiated thyroid carcinoma. During a median follow-up of 21.1 months, 27 patients experienced disease progression or death, and 10 died. The median PFS and OS were 46.3 and 76.0 months, respectively. In the primary multivariable model, a larger maximum pulmonary metastasis diameter (hazard ratio [HR] per 10-mm increase, 1.85; 95% confidence interval [CI], 1.20–2.73; p = 0.006) and absence of iodine-131 uptake (HR, 6.15; 95% CI, 1.73–37.55; p = 0.003) were associated with poorer PFS. The association between extrapulmonary distant metastases and PFS was not statistically significant in this model. Larger pulmonary metastases and absence of iodine-131 uptake were associated with poorer PFS after RAI. These findings require cautious interpretation and validation in larger independent cohorts.

Authors

Institutions

Publication Details

Journal
World Journal of Nuclear Medicine
Published
2026-11-19
DOI
https://doi.org/10.1055/s-0046-1830022
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Factors Associated with Progression-Free Survival after Radioiodine Therapy for Pulmonary Metastases from Follicular Cell-Derived Thyroid Carcinoma: A Japanese Single-Center Study

Tomokazu Hasegawa, Masanori Someya, Ryu Okuda, Mio Kitagawa et al.
World Journal of Nuclear Medicine
Thyroid Cancer Diagnosis and Treatment
article

Clinical Factors Associated with Progression-Free Survival after Radioiodine Therapy for Pulmonary Metastases from Follicular Cell-Derived Thyroid Carcinoma: A Japanese Single-Center Study

Tomokazu Hasegawa, Masanori Someya, Ryu Okuda, Mio Kitagawa, Toshio Gocho, Takaaki Tsuchiya, Ryo Kamiyama, Ryo Aota
article en

Abstract

This retrospective study aimed to identify clinical factors associated with progression-free survival (PFS) after radioiodine therapy (RAI) in Japanese patients with differentiated thyroid cancer (DTC) and pulmonary metastases. We included 74 patients with DTC and pulmonary metastases who underwent RAI at our institution between 2015 and 2023. Baseline clinicopathological, laboratory, and imaging variables at the initial RAI for pulmonary metastases were evaluated. PFS and overall survival (OS) were estimated using the Kaplan–Meier method. Because 27 PFS events were observed, associations with PFS were evaluated using Firth's penalized Cox regression. The primary multivariable model included the maximum pulmonary metastasis diameter, iodine-131 avidity, and extrapulmonary distant metastases. The cohort included 64 patients with papillary thyroid carcinoma, 7 with follicular thyroid carcinoma, and 3 with poorly differentiated thyroid carcinoma. During a median follow-up of 21.1 months, 27 patients experienced disease progression or death, and 10 died. The median PFS and OS were 46.3 and 76.0 months, respectively. In the primary multivariable model, a larger maximum pulmonary metastasis diameter (hazard ratio [HR] per 10-mm increase, 1.85; 95% confidence interval [CI], 1.20–2.73; p = 0.006) and absence of iodine-131 uptake (HR, 6.15; 95% CI, 1.73–37.55; p = 0.003) were associated with poorer PFS. The association between extrapulmonary distant metastases and PFS was not statistically significant in this model. Larger pulmonary metastases and absence of iodine-131 uptake were associated with poorer PFS after RAI. These findings require cautious interpretation and validation in larger independent cohorts.

World Journal of Nuclear Medicine
Sapporo Medical University (JP)
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon